Gsk (GSK) Total Liabilities (2009 - 2026)
Gsk (GSK) posted quarterly Total Liabilities of -$59.8 billion for Q2 2026, little changed year-over-year from -$59.7 billion in Q2 2025, and up 2.42% quarter-over-quarter from -$61.3 billion in Q1 2026.
Gsk (GSK) Total Liabilities (2009 - 2026) Analysis & Trends
Gsk's Total Liabilities history runs 18 years deep, the most recent figure standing at -$59.8 billion for Q2 2026.
- In Q2 2026, Total Liabilities changed 0.2% year-over-year to -$59.8 billion; the TTM figure through Jun 2026 stood at -$59.8 billion (changed 0.2% YoY), while the FY2025 annual figure was -$59.5 billion, down 200.45% from the prior year.
- Total Liabilities for Q2 2026 stood at -$59.8 billion, up from -$61.3 billion in the prior quarter.
- The five-year high for Total Liabilities was $59.5 billion in Q4 2024, with the low at -$83.6 billion in Q2 2022.
- The 5-year median for Total Liabilities is -$59.2 billion (2023), against an average of -$39.1 billion.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 69.01% in 2022, then plunged 200.92% in 2025.
- Gsk's Total Liabilities stood at $58.7 billion in 2022, then retreated by 2.3% to $57.4 billion in 2023, then increased by 3.79% to $59.5 billion in 2024, then plunged by 200.92% to -$60.1 billion in 2025, then rose by 0.48% to -$59.8 billion in 2026.
- Business Quant data shows GSK's Total Liabilities at -$59.8 billion in Q2 2026, -$61.3 billion in Q1 2026, and -$60.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.79 Bn |
| Mar 31, 2026 | -61.27 Bn |
| Dec 31, 2025 | -60.07 Bn |
| Sep 30, 2025 | -61.51 Bn |
| Jun 30, 2025 | -59.90 Bn |
| Mar 31, 2025 | -59.26 Bn |
| Dec 31, 2024 | 59.52 Bn |
| Sep 30, 2024 | -57.94 Bn |
| Jun 30, 2024 | -55.91 Bn |
| Mar 31, 2024 | -57.44 Bn |
| Dec 31, 2023 | 57.35 Bn |
| Sep 30, 2023 | -61.11 Bn |
| Jun 30, 2023 | -59.19 Bn |
| Mar 31, 2023 | -57.47 Bn |
| Dec 31, 2022 | 58.71 Bn |
| Sep 30, 2022 | -60.81 Bn |
| Jun 30, 2022 | -83.62 Bn |
| Mar 31, 2022 | -24.39 Bn |
| Dec 31, 2021 | 77.86 Bn |
| Sep 30, 2021 | -78.50 Bn |